<DOC>
	<DOCNO>NCT02099591</DOCNO>
	<brief_summary>To characterize pharmacokinetics ( PK ) naloxegol single oral dose population PK paediatric patient opioid induced constipation ( OIC ) .</brief_summary>
	<brief_title>Phase I Pharmacokinetics Safety Study Naloxegol Paediatric OIC Patients</brief_title>
	<detailed_description />
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Signs Symptoms</mesh_term>
	<mesh_term>Signs Symptoms , Digestive</mesh_term>
	<mesh_term>Analgesics , Opioid</mesh_term>
	<mesh_term>Naloxegol</mesh_term>
	<criteria>Main inclusion criterion , patient : malignant nonmalignant pain receiving ( receive ) acute chronic treatment opioids newly diagnose constatipation , history constipation treat laxative expect develop constipation opioid treatment ability present clinic least 10 hour follow first study drug blood sample return 24 hour blood sample . Main exclusion criterion : Current acute chronic use methadone History neoplasm ongoing gastrointestinalrelated issue Signs symptoms gastrointestinal obstruction History prolong neutropenia thrombocytopenia clinical sequela . Patients currently receive first cycle chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Constipation</keyword>
	<keyword>Colonic Inertia</keyword>
	<keyword>Dyschezia</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Naloxegol</keyword>
	<keyword>Paediatric</keyword>
	<keyword>Opioids</keyword>
	<keyword>Opioid induce constipation</keyword>
	<keyword>OIC</keyword>
	<keyword>Phase 1</keyword>
</DOC>